Clínica Baviera Acquires UK-Based Optimax Group for €11.7 Million

Clínica Baviera, through its subsidiary Castellana Intermediación Sanitaria, S.L., has finalized the purchase agreement to acquire 100% of the share capital of Optimax (Eye Hospitals Group Limited and its subsidiaries). This acquisition positions Clínica Baviera strategically within the UK market, adding to its established presence in Spain, Germany, and Italy.

The acquisition marks Clínica Baviera's strategic entry into the UK market, a significant move given the country's population of over 68 million. This expansion aligns with the company's growth strategy alongside its established presence in Spain, Germany, and Italy.

Financial Details of the Acquisition

The agreed acquisition amount totals over €11.7 million euros, which will be financed through Clínica Baviera's own funds. Additionally, a variable acquisition amount has been agreed upon, contingent on the Optimax’s EBITDA performance over the next 5 years, estimated to range between 3 and 11 million euros.

The transaction is subject to approval by the Financial Conduct Authority (FCA) due to the change in control of the Optimax Group. The deadline for fulfilling this suspensive condition has been set at six months.

About Optimax Group

Founded over 30 years ago, Optimax currently operates 19 clinics across major cities in the UK, specializing in refractive surgery and other ophthalmological services. With a team of over 130 professionals, the Group reported revenues of approximately €17 million in 2023, alongside losses nearing €1 million.